Evaxion reports three-year data for melanoma vaccine EVX-01
Evaxion A/S (EVAX) reported three-year data from its phase 2 trial of melanoma vaccine EVX-01, showing sustained clinical responses with no tumor progression. The data will be presented at the ESMO Congress 2026. Previously, two-year data showed a 75% objective response rate. EVX-01 is a personalized cancer vaccine currently being evaluated for advanced melanoma.
How this was made
The 30-second read
Why it matters
The three‑year follow‑up data strengthens the clinical profile of EVX‑01, potentially accelerating partnership talks and future financing.
Market read
First‑time disclosure of extended Phase 2 results is a material catalyst for EVAX and may affect biotech valuations broadly.
What to watch
Potential regulatory hurdles and competition from larger immunotherapy players could limit upside.
Background
Evaxion A/S is a Copenhagen‑based biotech developing AI‑driven personalized cancer vaccines.
Ticker impact
Evaxion disclosed three-year Phase 2 data for its melanoma vaccine EVX-01, showing sustained responses and no tumor progression.
upward pressure as the market prices in the encouraging efficacy results
Phase 2 data with no progression and strong immune responses is material for a biotech; first disclosure drives price reaction.
Market effects
Biotech sector may see renewed interest in personalized cancer vaccines.
European biotech investors could benefit as data presented at ESMO in Madrid.
Positive data may influence global oncology pipeline valuations.
Counterpoint
Skeptics may argue that Phase 2 data alone is insufficient without Phase 3 confirmation.
Key entities
- companyEvaxion A/S
Developer of the EVX‑01 melanoma vaccine.
- companyMerck
Partner providing pembrolizumab in the combination trial.
